has reached a milestone in data capture supporting the approval of new medical products. To date, global regulatory agencies have issued more than 300 approvals to biopharma companies that utilized ERT’s cardiac safety, respiratory, or eCOA solutions to capture safety and/or efficacy data in their clinical programs. ERT’s products and services for cardiac safety, respiratory, and eCOA include electronic patient reported outcomes (ePRO).
“It is extremely rewarding to realize that so many biopharmaceutical companies have brought new medical treatments to market using products and services delivered by ERT,” said Jeffrey Litwin, M.D., chief executive officer of ERT. “We are committed to delivering innovative and reliable solutions that meet the needs of our worldwide customers and supporting their efforts to bring life-enhancing and life-saving medical products to patients who need them.”